Ads
related to: abbvie pharmaceuticals- Read AbbVie Stories
Read Stories About Our Science,
People, and More Today.
- AbbVie News Center
See Our Achievements, Growth Story,
and More Today.
- Investor Resources
Find Financial Reports, Stock Info
And More Resources For Investors.
- Supporting Our Workforce
Embracing Equality & Diversity
Makes Us More Innovative.
- Read AbbVie Stories
Search results
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 13 hours agoAdditionally, AbbVie faces external threats from regulatory challenges and intellectual property disputes. By leveraging its strengths and addressing its...
AbbVie (ABBV) Could Be a Great Choice
Zacks via Yahoo Finance· 4 days agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?...
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks via Yahoo Finance· 3 days agoShares of this drugmaker have returned -10% over the past month versus the Zacks S&P 500 composite's...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 3 days agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
...NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims - Comfort Systems USA (NYSE:FIX), ...
Benzinga· 22 hours agoThe first-quarter 2024 earnings season is almost over as far as large drugmakers are concerned. Eli...
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool via Yahoo Finance· 6 days agoLast year, the company earned approval for Epkinly, a new cancer medicine that could reach peak sales of $3 billion in the U.S. alone, according to some...
Earnings call: AbbVie surpasses Q1 expectations, announces CEO transition By Investing.com
Investing.com· 5 days agoThe earnings call also marked a significant leadership transition, with CEO Rick Gonzalez announcing...
Barclays lowers AbbVie shares target on Humira sales erosion concerns By Investing.com
Investing.com· 5 days ago:ABBV) shares, reducing the price target to $187 from the previous $195. The revision was attributed...
Investors Take AbbVie To The Woodshed. But Its Woes Are 'Unfounded.'Investors Take AbbVie To The...
Investor's Business Daily· 5 days agoOn Friday, AbbVie beat first-quarter expectations, largely on the back of its immunology franchise....
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number ...
Ad
related to: abbvie pharmaceuticals
